METROPOLIS
Metropolis Healthcare
Each stock's 10,000-path forecast, rendered as light.
Metropolis Healthcare (METROPOLIS) Stock Analysis & Case Study
Is METROPOLIS a good buy? The data-driven verdict.
Metropolis Healthcare (METROPOLIS) trades at ₹540,on the numbers it tread carefully, a Downstox Snapshot Score of 41/100.
On the numbers, Metropolis Healthcare (METROPOLIS) tread carefully, a Downstox Snapshot Score of 41/100, weighing expensive at 57.1× earnings, ROE of 13.8%, a 53% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
METROPOLIS fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is METROPOLIS overvalued? METROPOLIS P/E vs its sector
METROPOLIS's P/E of 57.1× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.37% dividend yield is below the peer median of 1.65%.
METROPOLIS share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of METROPOLIS history (7%/yr drift, 29%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| METROPOLIS 2027 | ₹389 | ₹566 | ₹819 | +2% |
| METROPOLIS 2028 | ₹341 | ₹582 | ₹987 | +5% |
| METROPOLIS 2029 | ₹308 | ₹592 | ₹1,147 | +7% |
| METROPOLIS 2030 | ₹287 | ₹611 | ₹1,298 | +11% |
| METROPOLIS 2031 | ₹270 | ₹629 | ₹1,462 | +14% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability METROPOLIS goes up, or doubles?
The bull case for METROPOLIS
- A healthy 13.8% return on equity.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹1,147.
The bear case & risks
- A rich 57.1× P/E leaves a thin margin of safety if growth slows.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹308.
METROPOLIS volatility & expected range, how bumpy is the ride?
Over the last 2.0 years METROPOLIS compounded at 7%/year with annualized volatility of 29%. That volatility implies a 1-year 80% range of ₹389–₹819, the honest backbone behind any single price target.
METROPOLIS price forecast, the full 60-month probability fan
METROPOLIS price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds METROPOLIS hits common targets within the simulated horizon?
Full multi-horizon detail on the METROPOLIS price target & forecast page.
METROPOLIS Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. METROPOLIS scores 4/9,mixed financial health.
METROPOLIS MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy METROPOLIS with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.0% | 2.9× |
| ZerodhaCHEAPEST | 29.7% | 3.4× |
| DhanCHEAPEST | 29.7% | 3.4× |
Compare every broker on the METROPOLIS MTF page.
METROPOLIS vs peers,sector comparison
About Metropolis Healthcare: sector, index & market-cap context
Metropolis Healthcare (METROPOLIS) is a small-cap NSE-listed company, and a constituent of the Nifty 200 index group, with a market capitalisation of ₹11,217 Cr. See more Nifty 200 stocks.
How the METROPOLIS Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Metropolis Healthcare's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
METROPOLIS analysis, FAQs
Is Metropolis Healthcare (METROPOLIS) a good buy?
On the numbers, Metropolis Healthcare (METROPOLIS) tread carefully, a Downstox Snapshot Score of 41/100, weighing expensive at 57.1× earnings, ROE of 13.8%, a 53% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is METROPOLIS overvalued or undervalued?
METROPOLIS trades at 57.1× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the METROPOLIS share price target for 2031?
METROPOLIS's probability-weighted 2031 median target is ₹629, with an 80% range of ₹270–₹1,462 (10,000-path Monte-Carlo).
What is the probability METROPOLIS doubles in 5 years?
The modelled probability of METROPOLIS reaching ₹1,106 (2×) within 5 years is 19%.
What is the bull case for METROPOLIS?
A healthy 13.8% return on equity.
What are the risks in METROPOLIS?
A rich 57.1× P/E leaves a thin margin of safety if growth slows.